Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now official registry

Clinical Stage IVA Gastric Cancer AJCC v8 clinical trials

Every US clinical trial registered for Clinical Stage IVA Gastric Cancer AJCC v8 — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.

10 US clinical trials · 3 currently recruiting

The research picture

Clinical Stage IVA Gastric Cancer AJCC v8 has 10 registered US clinical trials, 3 of them open to new participants right now — about 30% of the total.

3
recruiting participants now
30%
of trials open to enrollment
1
in Phase 3–4 (later-stage)
6
top sponsor: M.D. Anderson Cancer Center

Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.

Active & Recent Trials

RECRUITING Phase 2 116 participants

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Academic and Community Cancer Research United

NCT04660760

RECRUITING Phase 1 49 participants

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

City of Hope Medical Center

NCT04329494

RECRUITING Early Phase 1 15 participants

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

M.D. Anderson Cancer Center

NCT05041153

ACTIVE NOT RECRUITING NA 750 participants

Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events

M.D. Anderson Cancer Center

NCT05038254

ACTIVE NOT RECRUITING Phase 3 314 participants

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

ECOG-ACRIN Cancer Research Group

NCT04248452

ACTIVE NOT RECRUITING Phase 2 240 participants

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

National Cancer Institute (NCI)

NCT05836584

ACTIVE NOT RECRUITING Phase 2 32 participants

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

M.D. Anderson Cancer Center

NCT03776487

ACTIVE NOT RECRUITING Phase 1 27 participants

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

M.D. Anderson Cancer Center

NCT04220827

ACTIVE NOT RECRUITING Phase 1 25 participants

Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma

M.D. Anderson Cancer Center

NCT04523818

COMPLETED Early Phase 1 9 participants

Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

M.D. Anderson Cancer Center

NCT03395847

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 3
Phase 3 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Clinical Stage IVA Gastric Cancer AJCC v8 Trial Landscape

ClinicalTrials.gov lists 10 US studies indexed under Clinical Stage IVA Gastric Cancer AJCC v8, and 3 of those are currently open to recruitment — roughly 30% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Clinical Stage IVA Gastric Cancer AJCC v8 shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 8 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Clinical Stage IVA Gastric Cancer AJCC v8 is led by M.D. Anderson Cancer Center with 6 indexed trials, alongside 4 other organizations in the top contributor list. The list on this page surfaces up to 10 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Clinical Stage IVA Gastric Cancer AJCC v8?

PlainTrial tracks 10 US clinical trials for Clinical Stage IVA Gastric Cancer AJCC v8, of which 3 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Clinical Stage IVA Gastric Cancer AJCC v8?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →